. WP-785 (Brequinar sodium) is a novel potent inhibitor of the pyrimidine de novo enzyme dihydrwrotic acid dehydrogenase (DHC-DH). We studied the relationship between DHC-DH activity and & vitro growth-inhibitory effects and in vivo antitumor effects of 3 8 5 . Seven cell lines from different histological origin were continuously exposed to CUP-785 for 48 hr. The human squamous carcinoma cell line 14C was most sensitive (IC50 0.19 pM), three other cell lines had a comparable IC50 of about 0.4 DM, while rat hepatoma H35 and murine leukemia Ll2lO had a IC50 of 2.6 and 5.9 pM, resp. DHD-DH activity varied between 15 and 20 nmo1,'i-Ir.lO6 cells in the cell lines tested. Inhibition by 1.3 pM WP-785 was 80-90% in the most sensitive lines, compared to 50% in H35 and 30% in L1210. The sensitivity of two murine colon tumors was investigated in vivo by injection of 50 mg/kg at day 0, 4, 8 and 12. The doubling time of Colon 26 for untreated and treated tumors was 2.7 and 2.8 days, resp, while for Colon 38 these values were 5.1 and 8.3 days, resp. DHC-DH activity was 230 and 167 nmol/hr per m9 protein, resp. In both tumors 50 mq CUP-785/kg decreased DHC-DH activity to below 10% after 4 hr, which was partly recovered after 1 day. After 1 day the concentration of uridine nucleotides in Colon 26 decreased by 30% and in Colon 38 by SO%, followed by an increase of 130 and 180%, resp, after 4 days. In conclusion; in vitro the extent of inhibition of WP-785 was related to the growth-inhibition, but in vivo this relation was less evident. At optimal CH THF concentration and 10 pM dUMP TS activity was 3-6 fold higher2than at 1 pM, both in tumors and mucosa. In mucosa TS activity at 10 pM d W was 44-107 pmol/hr per mg protein; in tumors from the same patient TS activity was always higher, but varied considerably between 52 and 3000, which is possibly related to tumor heterogeneity. 10 nM FdUMP inhibited TS activity 70-90%. The number of F d W binding sites at optimal CH,THF concentrations was 0.1-0.3 pmol FdW/mg protein in tumors and t0.1 in mucosa, but always 2-3 fold higher in the tumor. In vivo F d W binding was determined in tumor biopsies of patients obtained 1.5-3 hr after treatment with 500 mg 5FW/m2. FdUMP binding to the ternary complex was still complete; all binding sites were occupied by FdUMP. Currently the FdUMP binding in samples obtained at later time-points is being measured. In conclusion; TS activity was higher in tumors; inhibition by FdUMP was not only observed in vitro but also in vivo.
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SENSITIVITY TO PURINE ANTAGONISTS IN CHILDROOD LEUKEHIA ASSESSED BY THE AUTONATED HTT-ASSAY.
1 16 ~.pieters', D.R. Iiuismans1, A. ~e~va: A.J.P. veerman'.
Free University Hospital, Departments of pediatrics1 and Oncology: Amsterdam, The Netherlands.
We showed that in childhood common acute lymphoblastic leukemia (c-ALL), S'nucleotidase (5'NT) positive cases have a poorer prognosis than 5'NT negative cases. This might be due to the breakdown of the cytotoxic nucleotides of 6-mercaptopurine (6-MP) by high cytoplasmic 5'NT activities. Alternatively, ecto 5'NT can provide purine requirements of the purine salvage pathway aiid therefore rescue cells from a blockage of purine de novo synthesis by 6-MP and/or methotrexate. To test these hypothzses we need to determine the relation between these enzynes and drug sensitivity. We have adapted the MTT assay, which has only been reported on in studies dealing with established cell lines, to assess the chemosensitivity of cells obtained directly from patients. The assay is based on the reduction of MTT to formazan by living but not by dead cells. Formazd,~ production is quantitated automatically with a microplate spectrophotometer. Incubation of ALL cells with 6-MP (4-125 ug/ml) and 6-thioguanine (1.6-50 ug/ml) for 2-4 days resulted in dose-response curves covering the range from 0% to 100% cell survival. Comparison of thc MTT assay with a dye exclusion assay in 10 patients with ALL demonstrated an identical success rate and comparable doseresponse curves for both assays. Because automated quantitation of the chemosensitivity of leukemic cell samples involving about 80 drug concentrations takes only a few minutes with the NTT assay, this assay is a rapid, efficient, and objective method of measuring sensitivity to purine antagonists in ALL patients. We present a simplified model of purinf de novo synthesis consistxng in: (1) the administration of [ 4~]formate, (2) the determination in the nucleotides, of both concentrations and specific activity. (3) the calculation of the apparent rate constants (k -k -k ) for overall reactions involved in IMP, AMP and GMP f~rmiti;n,~through a system of differential equations.
We have evaluated the channeling of IMP into either GMP .or AMP ("the inosinic branch point") in vivo. The extraction of acid-soluble nucleotides, hydrolysis, purification of purine bases, lc$?termination of quantity and specific radioactivity after [ ~Iformate administration, was carried out according to Pizzichini et al., 1985 (1) . In the liver. kidney and other organs, of normal, adrenalectomized, castrated rats, we found (1) a different pattern for each type of tissue, (2) a preferential channeling of IMP into AMP under normal conditions, with remarkable variations in the individual situations. We were able to conclude that this critical metabolic point is under hormonal control.
(1) Pizzichini M., Di Stefano A., Marinello E. (1985) We have elaborated a biomathematical model of purine de novo synthesis in vivo, which is visualized as a series of monomolecular reactions, leading from formate to IMP, from IMP either to AMP or to GMP: k2-AMP formate---kl--*~M~~ k~ GMP The three most important steps in this sequence are evaluated in terms of apparent rate constants (k -k -k ) through a system of 1 2 3 differential equations, which includes the concentration and the specific radioactivity of the nucleotides after [14c]formate administration. Thus, we were able to follow (1) the rate of purine de novo synthesis in vivo in different rat organs (liver, kidney, spleen, heart), levator ani muscle, gastrocnemius and extensor digitorum longus, (2) the channeling of IMP into GMP or AMP (the "inosinic branch point"). Formation of IMP was most rapid in spleen, very fast in kidney, liver, heart, and lower in the muscles. The conversion of IMP into AMP was preferential in all tissues, an unexpectedly high rate of reaction IMP --GMP was evident in the heart.
